Trial · NCT02108171
Registered outcomes78
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 78
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Extubation Time After Intranasal Dexmedetomidine Premedication | 1 days | The times from stopping anesthetic infusions to adequate ventilation, consciousness and extubation after intranasal dexmedetomidine or placebo administration |
| Secondary | Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 days | Modified Observer's Assessment of Alertness/Sedation scale (OAA/S) scores and 4 point anxiety score of patients receiving intranasal placebo or dexmedetomidine. Modified Observer's Assessment of Alertness/Sedation Scale: 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus. |
| Secondary | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | Heart rate (HR) of patients receiving intranasal placebo or dexmedetomidine. HR was monitored in the study. |
| Secondary | Number of Participants With Anxiety Score >2 | 1 day | satisfaction using a 3-point satisfaction score (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable) anxiety levels using a 4-point anxiety score (1 = combative, 2 = anxious, 3 = calm, and 4 = amiable) were collected before intranasal drugs and at pre-induction. Anxiety score \>2 was considered to be better for the patient. |
| Secondary | Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | 4-point anxiety score: 1. = combative 2. = anxious 3. = calm 4. = amiable. Anxiety score \>2 was considered to be better for the preoperative patients. |
| Secondary | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | Systolic blood pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine. |
| Secondary | Number of Participants With Satisfaction Score <2 | 1 day | Patient satisfaction scores using a 3-point satisfaction score (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable) were collected when patients were discharged from the post-anesthesia care unit (PACU). Satisfaction score \<2 was considered to be better for the patient |
| Secondary | Perioperative Bradycardia Episodes | 1 day | Bradycardia was defined as heart rate (HR) \<45 bpm for more than 10 s. |
| Secondary | Perioperative Tachycardia Episodes | 1 day | Tachycardia was defined as heart rate (HR) \>100 bpm for more than 10 s. |
| Secondary | Perioperative Hypotension Episodes | 1 day | Hypotension was defined as systolic blood pressure (SBP) decreased more than 30% of the pre-operative value for more than 1 min. |
| Secondary | Perioperative Hypertonsion Episodes | 1 day | Hypertension was defined as systolic blood pressure (SBP) increased 130% of the pre-operative value for more than 1 min. |
| Other | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | 1 day | Baseline characteristic data of patients receiving intranasal placebo The weights of 41 adult patients receiving intranasal placebo |
| Other | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | 1 day | Baseline characteristic data of patients receiving intranasal dexmedetomidine The weights of 40 adult patients receiving intranasal dexmedetomidine |
| Other | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | 1 day | Baseline characteristic data of patients receiving intranasal placebo The heights of 41 adult patients receiving intranasal placebo |
| Other | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | 1 day | Baseline characteristic data of patients receiving intranasal dexmedetomidine The heights of 40 adult patients receiving intranasal placebo |
| Other | Baseline Characteristics (Sex)of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | Baseline characteristics (sex)of patients receiving intranasal placebo or dexmedetomidine The sex of 81 adult patients receiving intranasal placebo or dexmedetomidine |
| Other | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | American Society of Anesthesiologists (ASA) status of patients receiving intranasal placebo or dexmedetomidine. ASA I: No organic, physiologic, biochemical or psychiatric disturbance ASA II: A patient with mild systemic disease that results in no functional limitation. ASA III: A patient with severe systemic disease that results in functional impairment. ASA IV: Severe systemic disease that is a constant threat to life. ASA V: Moribund condition in a patient who is not expected to survive with or without the operation. ASA VI: Declared brain death patient whose organs are being harvested for transplantation. |
| Other | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | 1 day | Duration from intranasal drug administration to arrival at operating room of patients receiving intranasal placebo surgical data of patients receiving intranasal placebo |
| Other | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | 1 day | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal dexmedetomidine surgical data of patients receiving intranasal dexmedetomidine |
| Other | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | 1 day | Duration from intranasal drug administration to anesthesia intubation of Patients Receiving Intranasal Placebo surgical data of patients receiving intranasal placebo |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02108171/registered